The Pancreatic Cancer Action Network awarded the first PanCAN Therapeutic Accelerator Award to Verastem Oncology to evaluate their investigational treatments, VS-6766 and defactinib, in an early-stage (phase Ib/II) pancreatic ductal adenocarcinoma clinical trial.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe